<DOC>
	<DOCNO>NCT01410695</DOCNO>
	<brief_summary>The objective compare efficacy safety masitinib 3 6 mg/kg/day methotrexate , randomisation 1:1:1 , treatment patient active rheumatoid arthritis inadequate response 1. methotrexate 2. DMARD include least one biologic drug patient previously fail methotrexate 3. methotrexate combination DMARD include biologic drug .</brief_summary>
	<brief_title>A Phase 2b/3 Study Evaluate Efficacy Safety Masitinib Comparison Methotrexate Patients With Active Rheumatoid Arthritis With Inadequate Response Methotrexate Any Disease-Modifying Antirheumatic Drug</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Antirheumatic Agents</mesh_term>
	<criteria>1 . Patient rheumatoid arthritis diagnose accord American College Rheumatology ( ACR ) criteria least 6 month 2 . Patient ACR functional class IIII 3 . Patient active RA 4 . Patient fail ( define active RA stable dose 3 month ) methotrexate DMARD include biologics drug patient previously fail methotrexate methotrexate combination DMARD include biologics drug 5 . Patient disease onset &gt; 16 year age 1 . Patient use methotrexate contraindicate per SPC 2 . Patient document fibromyalgia 3 . Patient lactose intolerance 4 . Patient present cardiac disorder</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Rheumatoid Arthritis</keyword>
	<keyword>RA</keyword>
	<keyword>masitinib</keyword>
	<keyword>DMARD</keyword>
	<keyword>methotrexate</keyword>
</DOC>